OPKO Health, Inc. Proceeds from Sales of Assets, Investing Activities
OPKO Health, Inc. (OPK) reported Proceeds from Sales of Assets, Investing Activities of $197.77 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-10-29.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSalesOfAssetsInvestingActivities · last filed 2025-10-29
- 2025-09-30: Proceeds from Sales of Assets, Investing Activities 9 month $197.77M.
- 2024-09-30: Proceeds from Sales of Assets, Investing Activities 9 month $210.38M.
| Period end | Proceeds from Sales of Assets, Investing Activities 9 month |
|---|---|
| 2025-09-30 | $197.77M 10-Q · filed 2025-10-29 |
| 2024-09-30 | $210.38M 10-Q · filed 2025-10-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |